vs
Side-by-side financial comparison of Axos Financial, Inc. (AX) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $392.2M, roughly 1.8× Axos Financial, Inc.). Axos Financial, Inc. runs the higher net margin — 31.8% vs 19.1%, a 12.7% gap on every dollar of revenue. Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 16.1%).
Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
AX vs MEDP — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $392.2M | $708.5M |
| Net Profit | $124.7M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | — | 21.6% |
| Net Margin | 31.8% | 19.1% |
| Revenue YoY | — | 32.0% |
| Net Profit YoY | 18.5% | 15.5% |
| EPS (diluted) | $2.15 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $392.2M | — | ||
| Q4 25 | $385.1M | $708.5M | ||
| Q3 25 | $323.4M | $659.9M | ||
| Q2 25 | $321.4M | $603.3M | ||
| Q1 25 | $308.8M | $558.6M | ||
| Q4 24 | $307.9M | $536.6M | ||
| Q3 24 | $320.7M | $533.3M | ||
| Q2 24 | $290.9M | $528.1M |
| Q1 26 | $124.7M | — | ||
| Q4 25 | $128.4M | $135.1M | ||
| Q3 25 | $112.4M | $111.1M | ||
| Q2 25 | $110.7M | $90.3M | ||
| Q1 25 | $105.2M | $114.6M | ||
| Q4 24 | $104.7M | $117.0M | ||
| Q3 24 | $112.3M | $96.4M | ||
| Q2 24 | $104.9M | $88.4M |
| Q1 26 | — | — | ||
| Q4 25 | 45.6% | 21.6% | ||
| Q3 25 | 46.3% | 21.5% | ||
| Q2 25 | 48.5% | 20.9% | ||
| Q1 25 | 47.9% | 20.3% | ||
| Q4 24 | 48.8% | 23.4% | ||
| Q3 24 | 49.6% | 21.1% | ||
| Q2 24 | 49.6% | 19.9% |
| Q1 26 | 31.8% | — | ||
| Q4 25 | 33.3% | 19.1% | ||
| Q3 25 | 34.7% | 16.8% | ||
| Q2 25 | 34.4% | 15.0% | ||
| Q1 25 | 34.1% | 20.5% | ||
| Q4 24 | 34.0% | 21.8% | ||
| Q3 24 | 35.0% | 18.1% | ||
| Q2 24 | 36.0% | 16.7% |
| Q1 26 | $2.15 | — | ||
| Q4 25 | $2.22 | $4.65 | ||
| Q3 25 | $1.94 | $3.86 | ||
| Q2 25 | $1.89 | $3.10 | ||
| Q1 25 | $1.81 | $3.67 | ||
| Q4 24 | $1.80 | $3.67 | ||
| Q3 24 | $1.93 | $3.01 | ||
| Q2 24 | $1.75 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.1B | $459.1M |
| Total Assets | $29.2B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $497.0M | ||
| Q3 25 | $2.6B | $285.4M | ||
| Q2 25 | $1.9B | $46.3M | ||
| Q1 25 | $2.0B | $441.4M | ||
| Q4 24 | $2.4B | $669.4M | ||
| Q3 24 | $2.6B | $656.9M | ||
| Q2 24 | $2.0B | $510.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $312.7M | — | ||
| Q1 25 | $377.4M | — | ||
| Q4 24 | $358.7M | — | ||
| Q3 24 | $313.5M | — | ||
| Q2 24 | $325.7M | — |
| Q1 26 | $3.1B | — | ||
| Q4 25 | $2.9B | $459.1M | ||
| Q3 25 | $2.8B | $293.6M | ||
| Q2 25 | $2.7B | $172.4M | ||
| Q1 25 | $2.6B | $593.6M | ||
| Q4 24 | $2.5B | $825.5M | ||
| Q3 24 | $2.4B | $881.4M | ||
| Q2 24 | $2.3B | $763.6M |
| Q1 26 | $29.2B | — | ||
| Q4 25 | $28.2B | $2.0B | ||
| Q3 25 | $27.4B | $1.8B | ||
| Q2 25 | $24.8B | $1.6B | ||
| Q1 25 | $24.0B | $1.9B | ||
| Q4 24 | $23.7B | $2.1B | ||
| Q3 24 | $23.6B | $2.1B | ||
| Q2 24 | $22.9B | $1.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $192.7M | ||
| Q3 25 | $118.4M | $246.2M | ||
| Q2 25 | $490.3M | $148.5M | ||
| Q1 25 | $73.7M | $125.8M | ||
| Q4 24 | $162.5M | $190.7M | ||
| Q3 24 | $70.8M | $149.1M | ||
| Q2 24 | $305.5M | $116.4M |
| Q1 26 | — | — | ||
| Q4 25 | $85.4M | $188.1M | ||
| Q3 25 | $109.3M | $235.5M | ||
| Q2 25 | $436.1M | $142.4M | ||
| Q1 25 | $65.1M | $115.8M | ||
| Q4 24 | $156.4M | $183.0M | ||
| Q3 24 | $53.0M | $138.5M | ||
| Q2 24 | $269.5M | $103.5M |
| Q1 26 | — | — | ||
| Q4 25 | 22.2% | 26.6% | ||
| Q3 25 | 33.8% | 35.7% | ||
| Q2 25 | 135.7% | 23.6% | ||
| Q1 25 | 21.1% | 20.7% | ||
| Q4 24 | 50.8% | 34.1% | ||
| Q3 24 | 16.5% | 26.0% | ||
| Q2 24 | 92.6% | 19.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 0.6% | ||
| Q3 25 | 2.8% | 1.6% | ||
| Q2 25 | 16.9% | 1.0% | ||
| Q1 25 | 2.8% | 1.8% | ||
| Q4 24 | 2.0% | 1.4% | ||
| Q3 24 | 5.5% | 2.0% | ||
| Q2 24 | 12.4% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.81× | 1.43× | ||
| Q3 25 | 1.05× | 2.22× | ||
| Q2 25 | 4.43× | 1.65× | ||
| Q1 25 | 0.70× | 1.10× | ||
| Q4 24 | 1.55× | 1.63× | ||
| Q3 24 | 0.63× | 1.55× | ||
| Q2 24 | 2.91× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
